Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: A meta-analysis

doi:10.3748/wjg.v16.i23.2931

	Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: A meta-analysis
	Miao, Ruo-Yu 1,2; Zhao, Hai-Tao 1,2; Yang, Hua-Yu 1,2; Mao, Yi-Lei 1,2; Lu, Xin 1,2; Zhao, Yi 3; Liu, Chang-Ning 3; Zhong, Shou-Xian 1,2; Sang, Xin-Ting 1,2; Huang, Jie-Fu 1,2
	2010-06-21
发表期刊	WORLD JOURNAL OF GASTROENTEROLOGY
ISSN	1007-9327
卷号	16 期号:23 页码:2931-2942
摘要	AIM: To investigate the impact of postoperative antiviral treatment on tumor recurrence and survival of patients with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection-related primary hepatocellular carcinoma (HCC) after curative therapy. METHODS: We performed a meta-analysis of randomized and non-randomized control trials from electronic search and manual search. The fixed effect model of Mantel-Haenszel method and the random effect model of Der Simonian and Laird method were used for homogeneous and heterogeneous studies, respectively. Seven HCV-related studies, three HBV-related studies and three studies on HBV or HCV-related HCC were identified. RESULTS: A total of 1224 patients were included in this analysis. The estimated odds ratios (OR) for the 1-, 2-, 3- and 5-year recurrence were 0.54 [15.4% vs 24.1%, 95% confidence interval (CI): 0.32-0.89, P = 0.02], 0.42 (36.9% vs 58.0%, 95% CI: 0.19-0.90, P = 0.03), 0.37 (47.9% vs 63.8%, 95% CI: 0.19-0.71, P = 0.003), and 0.32 (66.7% vs 74.3%, 95% CI: 0.15-0.66, P = 0.002), respectively; and the OR for the 1-, 2-, 3-, 5- and 7-year mortality were 0.23 (1.2% vs 9.1%, 95% CI: 0.07-0.71, P = 0.01), 0.31 (6.4% VS 22.1%, 95% CI: 0.12-0.79, P = 0.01), 0.43 (12.7% vs 20.8%, 95% CI: 0.21-0.89, P = 0.02), 0.42 (25.1% vs 42.0%, 95% CI: 0.27-0.66, P = 0.0002) and 0.28 (31.9% vs 52.2%, 95% CI: 0.13-0.59, P = 0.0008). CONCLUSION: This meta-analysis indicates the postoperative antiviral therapy, interferon in particular, may serve as a favorable alternative to reduce recurrence and mortality in patients with HBV/HCV related HCCs. (C) 2010 Baishideng. All rights reserved.
关键词	Antiviral therapy Hepatitis B virus Hepatitis C virus Hepatocellular carcinoma Recurrence Survival
DOI	10.3748/wjg.v16.i23.2931
收录类别	SCI
语种	英语
资助项目	National Natural Science Foundation of China[30970623] ; National Natural Science Foundation of China[30600729] ; International Science and Technology Cooperation[2010DFA31840]
WOS研究方向	Gastroenterology & Hepatology
WOS类目	Gastroenterology & Hepatology
WOS记录号	WOS:000279034500014
出版者	W J G PRESS
引用统计	被引频次：61[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://119.78.100.204/handle/2XEOYT63/12291
专题	中国科学院计算技术研究所期刊论文_英文
通讯作者	Zhao, Hai-Tao
作者单位	1.Chinese Acad Med Sci, Dept Liver Surg, Peking Union Med Coll Hosp, Beijing 100730, Peoples R China 2.Peking Union Med Coll, Beijing 100730, Peoples R China 3.Chinese Acad Sci, Bioinformat Res Grp, Inst Comp Technol, Beijing 100190, Peoples R China
推荐引用方式 GB/T 7714	Miao, Ruo-Yu,Zhao, Hai-Tao,Yang, Hua-Yu,et al. Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: A meta-analysis[J]. WORLD JOURNAL OF GASTROENTEROLOGY,2010,16(23):2931-2942.
APA	Miao, Ruo-Yu.,Zhao, Hai-Tao.,Yang, Hua-Yu.,Mao, Yi-Lei.,Lu, Xin.,...&Huang, Jie-Fu.(2010).Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: A meta-analysis.WORLD JOURNAL OF GASTROENTEROLOGY,16(23),2931-2942.
MLA	Miao, Ruo-Yu,et al."Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: A meta-analysis".WORLD JOURNAL OF GASTROENTEROLOGY 16.23(2010):2931-2942.